Understanding Stem Cells: Types, Sources, and Potency Explained

Stem cells are unspecialized cells with the capacity to divide and differentiate into specialized cell types. This article explains the main categories of stem cells, their sources, and the concept of potency for laboratory students, technicians, researchers, and diagnostic professionals. The content focuses on the scientific principles that govern stem cell classification and the practical considerations for working with these cells in a laboratory setting.

At a Glance: Stem Cell Types and Potency

The table below summarizes the primary stem cell categories, their sources, differentiation potential, and key laboratory considerations.

Defining Stem Cell Potency

Potency describes the range of differentiation options available to a stem cell. The potency hierarchy ranges from totipotent cells, which can form all embryonic and extraembryonic tissues, to unipotent cells, which generate only one mature cell type. Understanding this hierarchy is fundamental to selecting appropriate cell types for research or therapeutic applications.

Totipotent cells represent the highest level of developmental potential. In mammalian development, only the zygote and early cleavage-stage blastomeres are truly totipotent because they can generate both the embryo and the supporting extraembryonic tissues such as the placenta. Research has demonstrated that stable totipotent-like stem cell cultures can be derived through chemical approaches that remodel chromatin structure, specifically by targeting pericentromeric heterochromatin and re-establishing totipotency-specific histone modification patterns. These totipotent-like stem cells show functional competence for germline transmission and can contribute to both embryonic and extraembryonic lineages at high frequency, making them valuable for studying early developmental events.

Pluripotent stem cells sit below totipotent cells in the potency hierarchy. These cells can generate all cell types of the adult organism but show limited contribution to extraembryonic placental tissues. Extended pluripotent stem cells represent a recently described state that expands the developmental potential of conventional pluripotent stem cells. Research has shown that a chemical cocktail can derive stem cells from mice and humans that are capable of chimerizing both embryonic and extraembryonic tissues, and a single mouse extended pluripotent stem cell can contribute to both lineages in vivo.

Multipotent stem cells are restricted to differentiating into cell types within a particular germ layer or tissue lineage. Mesenchymal stem cells exemplify this category, as they can differentiate into osteoblasts, chondrocytes, myocytes, and adipocytes. These cells have been extensively studied for their therapeutic potential in inflammatory and degenerative diseases, with multiple strategies explored to enhance their stemness and therapeutic effectiveness.

Unipotent stem cells represent the most restricted category, producing only one mature cell type. Tissue-resident stem cells in organs such as the skin, intestine, and liver often fall into this category, maintaining tissue homeostasis through controlled self-renewal and differentiation.

Embryonic Stem Cells

Embryonic stem cells are derived from the inner cell mass of the blastocyst, a structure that forms approximately five days after fertilization in humans. These cells are pluripotent, meaning they can differentiate into all cell types of the three germ layers: ectoderm, mesoderm, and endoderm.

The defining features of embryonic stem cells include their capacity for prolonged undifferentiated proliferation in culture and their ability to maintain a normal karyotype over extended passage. These properties make them valuable research tools for studying developmental biology and for potential therapeutic applications. However, the derivation of embryonic stem cells requires the destruction of the blastocyst, which raises ethical considerations that vary across jurisdictions and institutional policies.

Laboratory work with embryonic stem cells requires rigorous quality control. Cultures must be monitored for spontaneous differentiation, which can occur when culture conditions are suboptimal. Markers of pluripotency, including transcription factors such as OCT4 and NANOG, should be assessed regularly to confirm that cells maintain their undifferentiated state. Teratoma formation assays in immunocompromised mice provide functional evidence of pluripotency, as the resulting tumors contain tissues from all three germ layers.

The clinical translation of embryonic stem cell derivatives has been explored for various conditions. In cardiovascular research, embryonic stem cells and their derivatives have been applied in clinical trials, although results have been inconsistent and the improvement of heart performance and cardiac remodeling has been limited. These findings highlight the gap between preclinical promise and clinical reality, emphasizing the need for continued mechanistic research.

Adult Stem Cells

Adult stem cells, also called somatic stem cells, reside in differentiated tissues and maintain or repair those tissues throughout life. Unlike embryonic stem cells, adult stem cells are typically multipotent or unipotent, with differentiation capacity limited to cell types within their tissue of origin.

Mesenchymal stem cells are among the most studied adult stem cell populations. These multipotent stromal cells can differentiate into osteoblasts, chondrocytes, myocytes, and adipocytes. They have been investigated extensively for therapeutic applications in inflammatory and degenerative diseases, with multiple preclinical investigations and clinical trials employing enhanced mesenchymal stem cell therapies. Strategies to improve their therapeutic potency include treatment with pharmaceutical compounds, cytokines, growth factors, hormones, and vitamins, which have shown potential in boosting stemness.

Hematopoietic stem cells reside in the bone marrow and give rise to all blood cell lineages. These cells have a long history of clinical use, particularly in the treatment of hematological malignancies. In Hodgkin lymphoma, for example, recurrent or refractory disease can be treated with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. This application demonstrates the clinical utility of adult stem cells when their differentiation capacity matches the therapeutic need.

Organ-specific stem cells maintain tissues such as the skin, intestine, and skeletal muscle. Skeletal muscle stem cells, also called satellite cells, reside between the basal lamina and the sarcolemma of muscle fibers. Single-cell and spatial transcriptomic studies have revealed the cellular heterogeneity of skeletal muscle development and the molecular regulatory networks that control muscle stem cell behavior, including the composition of the niche, intercellular communication, and mechanical cues.

Thyroid resident stem cells and thyroid cancer stem cells have been identified as important populations in thyroid biology. These cells play roles in forming organ-specific cells and cancers, and stem cells, especially mesenchymal stem cells, have demonstrated anti-inflammatory and anticancer functions relevant to thyroid disease. The therapeutic applications of stem cells for thyroid disorders include thyroid cell regeneration, thyroid function modulation, thyroiditis suppression, and antithyroid cancer activity.

Induced Pluripotent Stem Cells

Induced pluripotent stem cells, commonly abbreviated as iPSCs, are generated by reprogramming somatic cells to a pluripotent state. The landmark discovery that differentiated cells could be reprogrammed by introducing defined transcription factors transformed the stem cell field. Initial work demonstrated that mouse embryonic and adult fibroblasts could be induced to a pluripotent state by introducing four factors: Oct3/4, Sox2, c-Myc, and Klf4. These induced pluripotent stem cells exhibited the morphology and growth properties of embryonic stem cells, expressed embryonic stem cell marker genes, and contributed to mouse embryonic development following injection into blastocysts.

Subsequent research extended this approach to adult human fibroblasts, confirming that the reprogramming strategy could be applied across species. Refinements to the original protocol demonstrated that induced pluripotent stem cells could be generated without the oncogene Myc, improving the safety profile of the resulting cells for potential therapeutic applications.

The molecular mechanisms underlying reprogramming are complex and involve extensive epigenetic remodeling. Somatic cells must reset their DNA methylation patterns and chromatin structure to achieve a pluripotent state. Research has shown that low-passage induced pluripotent stem cells derived by factor-based reprogramming harbor residual DNA methylation signatures characteristic of their somatic tissue of origin. This epigenetic memory favors differentiation along lineages related to the donor cell while restricting alternative cell fates. The memory can be reset by differentiation and serial reprogramming or by treatment with chromatin-modifying drugs.

Induced pluripotent stem cells have transformed in vitro research because they offer the capacity for almost unlimited expansion, are amenable to genetic engineering, and can be differentiated into most somatic cell types. They have been widely applied to model human development and diseases, perform drug screening, and develop cell therapies. Applications include neurological disorders, COVID-19, and cancer, where disease-specific phenotypes can be modeled using iPSC-derived cells.

The therapeutic potential of induced pluripotent stem cells has driven extensive research into their safety and efficacy. One approach to overcoming immune rejection of allogeneic cell products involves engineering hypoimmunogenic cells. Research has shown that both mouse and human induced pluripotent stem cells lose their immunogenicity when major histocompatibility complex class I and II genes are inactivated and CD47 is overexpressed. These hypoimmunogenic cells retain their pluripotent potential and differentiation capacity, and derivatives such as endothelial cells, smooth muscle cells, and cardiomyocytes can evade immune rejection in fully mismatched allogeneic recipients without immunosuppression.

Induced pluripotent stem cells have also been used to generate immune cells for cancer therapy. CD70-targeted, induced pluripotent stem cell-derived CAR-natural killer cells have been developed as an approach for universal immune cell therapy. These cells are modified with CD70 gene knockout, a high-affinity non-cleavable CD16, and an interleukin-15 receptor alpha/IL-15 fusion protein. They exhibit robust cytotoxicity against a wide range of tumors and can eliminate alloreactive T cells, improving their survival and persistence.

Chemical Reprogramming Approaches

Chemical reprogramming represents an alternative strategy for generating stem cells without genetic manipulation. This approach uses small molecules to control somatic cell fate and generate desired cell types, including pluripotent stem cells. Chemical reprogramming offers the potential for precise, flexible, and controllable manipulation of cell fate.

Recent success in the chemical reprogramming of human somatic cells has been achieved by activating a regeneration-like program, providing an alternative way of producing stem cells for clinical translation. Chemical manipulation enables the capture of multiple stem cell states, ranging from totipotency to the stabilization of somatic fates in vitro.

The advantages of chemical reprogramming include the absence of genomic integration, reduced risk of insertional mutagenesis, and the ability to fine-tune the reprogramming process through dose and timing adjustments. However, chemical reprogramming protocols are generally less efficient than transcription factor-based methods, and the resulting cells require thorough characterization to confirm their pluripotent status.

Potency Assessment Methods

Assessing stem cell potency requires a combination of molecular, cellular, and functional assays. No single assay provides complete information about differentiation potential, so a comprehensive approach is necessary.

Molecular characterization typically involves analysis of pluripotency-associated transcription factors and surface markers. Quantitative PCR and immunocytochemistry can confirm the expression of markers such as OCT4, SOX2, and NANOG. Epigenetic analysis, including DNA methylation profiling and histone modification analysis, provides additional information about the epigenetic state of the cells.

Functional assessment of potency involves demonstrating differentiation capacity. In vitro differentiation assays direct cells toward specific lineages and confirm the production of lineage-specific markers. Teratoma formation assays in immunocompromised mice provide the gold standard evidence of pluripotency, as the resulting tumors should contain tissues from all three germ layers. Chimera formation assays, in which candidate cells are injected into blastocysts and the resulting embryos are examined for contribution to various tissues, provide the most stringent test of developmental potency.

In silico diagnostics have been developed to complement experimental potency assessment. These computational approaches analyze gene expression and epigenetic data to predict differentiation potential, offering a faster and less resource-intensive alternative to animal-based assays. However, computational predictions require experimental validation and cannot fully replace functional testing.

Laboratory Workflow for Stem Cell Handling

Working with stem cells in a laboratory setting requires strict adherence to quality management principles and biosafety practices. The World Health Organization provides guidance on laboratory quality management systems and biosafety that applies to stem cell culture work.

The laboratory workflow for stem cell handling begins with source material acquisition and documentation. For established cell lines, this includes verifying the identity and passage number of the cells. For primary cells, documentation must include donor information, tissue source, and collection date, with appropriate attention to informed consent and ethical approval requirements.

Culture conditions must be optimized for each stem cell type. Pluripotent stem cells require defined media formulations and appropriate extracellular matrix substrates to maintain their undifferentiated state. Adult stem cells have varying requirements depending on their tissue of origin. Mesenchymal stem cells, for example, are typically cultured on tissue culture plastic in media supplemented with fetal bovine serum or defined serum replacements.

Quality control checks should be performed at defined intervals throughout the culture period. These include:

1. Daily microscopic observation for morphological changes, contamination, or spontaneous differentiation
2. Regular assessment of cell viability and proliferation rates
3. Periodic testing for mycoplasma contamination
4. Confirmation of stem cell marker expression at defined passage intervals
5. Karyotype analysis at regular intervals to detect chromosomal abnormalities

Records must be maintained for all culture activities, including media preparation, passaging, cryopreservation, and quality control results. The World Health Organization Laboratory Quality Management System Handbook provides a framework for establishing and maintaining such records in a diagnostic laboratory context.

Biosafety Considerations

Stem cell culture work requires adherence to biosafety practices appropriate for the cell types and any associated reagents. The World Health Organization Laboratory Biosafety Manual provides guidance on risk assessment and containment measures for biological materials.

Pluripotent stem cells require Biosafety Level 2 practices in most institutional settings. This includes the use of biological safety cabinets for all manipulations, appropriate personal protective equipment, and decontamination procedures for waste materials. Additional precautions may be required when working with genetically modified cells or cells derived from donors with known infectious diseases.

The tumorigenic potential of pluripotent stem cells presents a specific safety concern. Undifferentiated pluripotent cells can form teratomas when transplanted into immunocompromised animals, and this property must be considered when designing differentiation protocols and quality control assays. Strategies to eliminate residual undifferentiated cells from differentiated products are an active area of research.

Chemical reagents used in stem cell culture, including small molecule inhibitors and growth factors, require appropriate handling and documentation. Material safety data sheets should be reviewed before use, and exposure controls should be implemented as recommended.

Common Failure Patterns in Stem Cell Culture

Several recurring problems can compromise stem cell cultures. Recognizing these patterns early allows for corrective action before cultures are lost.

Spontaneous differentiation is a common problem in pluripotent stem cell culture. This appears as morphological changes in colony edges or centers, with cells losing their characteristic compact morphology. Common causes include suboptimal media formulations, excessive passaging, and inappropriate cell density. Corrective actions include adjusting culture conditions, increasing the frequency of media changes, and reseeding at appropriate densities.

Mycoplasma contamination is a persistent threat to cell culture laboratories. Mycoplasma infections do not cause obvious media turbidity and can go undetected for extended periods. Infected cultures may show reduced proliferation rates, altered morphology, and changes in gene expression that compromise experimental results. Regular testing using PCR-based or culture-based methods is essential, and contaminated cultures should be discarded and the source of contamination identified.

Karyotypic abnormalities can arise during extended culture of pluripotent stem cells. Chromosomal aberrations, particularly gains of chromosomes 12, 17, and X, have been reported in human embryonic stem cells and induced pluripotent stem cells. These abnormalities can confer a growth advantage, leading to their selection during passaging. Regular karyotype analysis is recommended to detect such changes before they compromise experimental outcomes.

Epigenetic instability can affect the differentiation potential of stem cells. As discussed earlier, induced pluripotent stem cells may retain epigenetic memory of their tissue of origin, which can bias differentiation toward donor-related lineages. This memory can be reduced through serial passaging or treatment with chromatin-modifying drugs, but it cannot be completely eliminated in all cell lines.

Limitations and Interpretation Constraints

Stem cell research has inherent limitations that must be considered when interpreting experimental results and planning therapeutic applications.

The translation of stem cell therapies from preclinical models to clinical practice has proven challenging. In cardiovascular disease, for example, stem cell therapy has shown promise in clinical trials, but results are inconsistent and the improvement of heart performance and cardiac remodeling has been limited. The mechanisms mediating the beneficial effects of stem cell transplantation are not fully understood, and the complexity of cardiovascular diseases makes it difficult to provide a uniform therapeutic intervention for all patient subgroups.

Cell retention and survival after transplantation remain significant obstacles. Poor cell retention, electrical and structural immaturity of transplanted cells, immune-mediated clearance, and concerns regarding tumorigenicity and arrhythmogenicity have limited the efficacy of cell-based cardiac therapies. The therapeutic efficacy of transplanted cells largely derives from paracrine signaling, including extracellular vesicles, secreted microRNAs, and pro-survival cytokines, instead of direct replacement of damaged tissue.

The functional maturity of stem cell-derived products is another limitation. Induced pluripotent stem cell-derived beta cells, for example, can secrete insulin in response to glucose, but achieving full functional maturity remains a challenge. Variability in differentiation efficiency, limited maturity, and poor long-term survival continue to hinder clinical translation of these cells for diabetes therapy.

Ethical considerations surrounding stem cell sourcing require careful attention. The use of embryonic stem cells raises questions about the moral status of embryos, and policies vary across jurisdictions. The CuRe Trial, which uses early gestational placental mesenchymal stromal cells for in utero repair of myelomeningocele, has raised ethical questions regarding tissue sourcing, particularly whether cells are obtained from miscarriage or elective abortion. These considerations affect research funding, regulatory approval, and public acceptance of stem cell therapies.

Professional Escalation Criteria

Laboratory personnel should escalate concerns to supervisors or institutional oversight bodies when specific conditions are identified. These escalation criteria help ensure that problems are addressed promptly and appropriately.

Escalate when contamination is suspected or confirmed. Mycoplasma, bacterial, or fungal contamination requires immediate action to protect other cultures and the integrity of the laboratory. The contaminated culture should be quarantined, and the source of contamination should be investigated before resuming normal operations.

Escalate when karyotypic abnormalities are detected. Chromosomal changes in pluripotent stem cell cultures may compromise experimental validity and preclude therapeutic use. The affected cell line should be quarantined, and the passage history should be reviewed to identify when the abnormality may have arisen.

Escalate when unexpected differentiation or loss of stem cell marker expression occurs. This may indicate problems with culture conditions, media components, or the genetic stability of the cells. A systematic investigation should be initiated to identify the cause before experiments continue.

Escalate when results from potency assays are inconsistent or unexpected. Discrepancies between molecular characterization and functional assays may indicate that the cells are not truly pluripotent or that assay conditions are suboptimal. The assays should be reviewed, and the cells should be recharacterized before conclusions are drawn.

Escalate when ethical or regulatory concerns arise regarding cell sourcing or research conduct. Institutional review boards and ethics committees exist to provide guidance on these matters, and their input should be sought before proceeding with research that raises questions about consent, tissue sourcing, or compliance with applicable regulations.

Frequently Asked Questions

What is the difference between totipotent and pluripotent stem cells?

Totipotent cells can generate all cell types of the organism plus the extraembryonic tissues such as the placenta. In mammals, only the zygote and early cleavage-stage blastomeres are truly totipotent. Pluripotent cells can generate all cell types of the adult organism but show limited contribution to extraembryonic tissues. Embryonic stem cells and induced pluripotent stem cells are pluripotent.

Where do mesenchymal stem cells come from?

Mesenchymal stem cells are found in multiple tissues, including bone marrow, adipose tissue, and umbilical cord tissue. They are multipotent stromal cells that can differentiate into osteoblasts, chondrocytes, myocytes, and adipocytes. Placental mesenchymal stromal cells have also been used in clinical research applications.

How are induced pluripotent stem cells generated?

Induced pluripotent stem cells are generated by introducing defined transcription factors into somatic cells. The original protocol used Oct3/4, Sox2, c-Myc, and Klf4 to reprogram mouse fibroblasts. Subsequent work extended this approach to human fibroblasts and refined the factor combinations to improve safety and efficiency.

What is epigenetic memory in induced pluripotent stem cells?

Epigenetic memory refers to residual DNA methylation signatures in induced pluripotent stem cells that are characteristic of their somatic tissue of origin. This memory can bias differentiation toward lineages related to the donor cell while restricting alternative cell fates. It can be reset by differentiation and serial reprogramming or by treatment with chromatin-modifying drugs.

Can stem cells be generated without genetic manipulation?

Yes, chemical reprogramming uses small molecules to control somatic cell fate and generate desired cell types, including pluripotent stem cells. This approach offers precise and controllable manipulation of cell fate without genomic integration. Recent success has been achieved in the chemical reprogramming of human somatic cells.

What are the main safety concerns with pluripotent stem cells?

The tumorigenic potential of undifferentiated pluripotent cells is a primary safety concern, as they can form teratomas when transplanted. Additional concerns include immune rejection of transplanted cells and the potential for genetic instability during extended culture. Hypoimmunogenic engineering approaches have been developed to address immune rejection.

How is stem cell potency assessed in the laboratory?

Potency assessment combines molecular characterization, including marker expression and epigenetic analysis, with functional assays. In vitro differentiation assays confirm lineage potential, while teratoma formation in immunocompromised mice provides evidence of pluripotency. Chimera formation assays provide the most stringent test of developmental potency.

What are the limitations of stem cell therapies?

Clinical translation of stem cell therapies has been limited by poor cell retention and survival after transplantation, functional immaturity of differentiated products, immune-mediated clearance, and concerns about tumorigenicity. The therapeutic efficacy of transplanted cells often derives from paracrine signaling instead of direct cell replacement, and outcomes have been inconsistent across clinical trials.

Related Diagnostic Guides

• Understanding Competent Cells: Types, Preparation, and Storage for Transformation
• How to Calculate Cell Concentration Using a Hemocytometer
• How to Calculate the Number of Cells in a Confluent Monolayer
• Understanding DNA Ligase: Mechanism, Types, and Role in Replication and Cloning
• Understanding Laboratory Balance Calibration: Types, Procedures, and Quality Checks

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives.. Cell stem cell, 2023.
• Enhancers of mesenchymal stem cell stemness and therapeutic potency.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023.
• Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency.. Cell, 2017.
• Hodgkin lymphoma.. Nature reviews. Disease primers, 2020.
• Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies.. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018.
• Chemical-induced chromatin remodeling reprograms mouse ESCs to totipotent-like stem cells.. Cell stem cell, 2022.
• CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells.. Cell reports. Medicine, 2025.
• Stem Cell Therapy for Thyroid Diseases: Progress and Challenges.. Current therapeutic research, clinical and experimental, 2022.
• Current status of neural progenitor/stem cells for spinal cord injury: fundamental research and clinical trials
• The CuRe Trial: Groundbreaking Innovation Raising Scientific and Ethical Questions.. 2026.
• Deciphering skeletal muscle development: cellular heterogeneity and molecular regulatory networks from single-cell and spatial transcriptomic perspectives.. 2026.
• Engineering cardiac regeneration using stem cells: Cellular sources, differentiation signatures, targeted delivery, and functional recovery.. 2026.
• Mesenchymal stromal/stem cells for neurological disorders in humans: an evidence-mapped clinical review
• Beyond quality control: biological roles of nonsense-mediated RNA decay.. 2026.
• The context-dependent role of the dsRNA response in linking A-to-I editing and ADAR to normal hematopoiesis and leukemia
• Bioengineering Pancreatic Organoids and iPSC-Derived β-Cells for Diabetes: Materials, Devices, and Translational Challenges.. 2026.
• Generation of germline-competent induced pluripotent stem cells. Nature, 2007.
• Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotechnology, 2008.
• Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduction and Targeted Therapy, 2024.
• Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.. Cell, 2006.
• Induction of pluripotent stem cells from adult human fibroblasts by defined factors.. Cell, 2007.
• Epigenetic memory in induced pluripotent stem cells. Nature, 2010.
• Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nature Biotechnology, 2019.
• Describing the stem cell potency: The various methods of functional assessment and in silico diagnostics. Frontiers in Cell and Developmental Biology, 2016.
• Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. Journal of the American College of Cardiology, 2012.
• Pluripotent stem cells and their therapeutic applications. Gene and Cell Therapy Therapeutic Mechanisms and Strategies Fourth Edition, 2015.
• Ptip safeguards the epigenetic control of skeletal stem cell quiescence and potency in skeletogenesis. Science Bulletin, 2024.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.